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Abstract
Background: Glioblastoma multiforme is the most aggressive malignant primary brain tumor, characterized by
rapid growth and extensive infiltration to neighboring normal brain parenchyma. Both PI3K/Akt and JNK pathways
are essential to glioblastoma cell survival, migration and invasion. Due to their hyperactivation in glioblastoma cells,
PI3K and JNK are promising targets for glioblastoma treatment.
Methods: To investigate the combination effects of class IA PI3K catalytic isoforms (p110α, p110β and p110δ) and
JNK inhibition on tumor cell growth and motility, glioblastoma cells and xenografts in nude mice were treated with
isoform-selective PI3K inhibitors in combination with JNK inhibitor.
Results: We showed that combined inhibition of these PI3K isoforms and JNK exerted divergent effects on the
proliferation, migration and invasion of glioblastoma cells in vitro. Pharmacological inhibition of p110β or p110δ, but
not p110α, displayed synergistic inhibitory effect with JNK inhibition on glioblastoma cell proliferation and migration
through decreasing phosphorylation of Akt, FAK and zyxin, leading to blockade of lamellipodia and membrane ruffles
formation. No synergistic effect on invasion was observed in all the combination treatment. In vivo, combination of
p110β and JNK inhibitors significantly reduced xenograft tumor growth compared with single inhibitor alone.
Conclusion: Concurrent inhibition of p110β and JNK exhibited synergistic effects on suppressing glioblastoma cell
proliferation and migration in vitro and xenograft tumor growth in vivo. Our data suggest that combined inhibition of
PI3K p110β isoform and JNK may serve as a potent and promising therapeutic approach for glioblastoma multiforme.
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Background
Glioblastoma multiforme (GBM) is the most common
aggressive and malignant primary tumor in the central
nervous system. GBM is classified as WHO grade IV
glioma, characterized by rapid growth and extensive
infiltration to neighboring normal brain parenchyma,
which prevents complete surgical resection and leads to
tumor recurrence and poor prognosis [1, 2]. Thus, mi-
gration and invasion of glioblastoma cells are potential
therapeutic targets for GBM treatment.
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases
involved in a variety of biological responses including
cell proliferation metabolism, motility, survival and
angiogenesis [3]. Inhibition of PI3K activity suppresses
formation of lamellipodia and membrane ruffles, indi-
cating PI3K/Akt pathway may regulate cell migration
through mediating actin filament remodeling [4–6].
Class IA PI3K is activated by receptor tyrosine kinases
(RTKs) and is composed of a heterodimer consisting of
a 110 kDa catalytic subunit (p110α, p110β and p110δ)
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and a 85 kDa regulatory subunit [3]. The pan-PI3K
inhibitors wortmannin and LY294002 are limited in
clinical use due to their poor pharmaceutical properties,
unacceptable toxicities and off-target effects. Although a
number of novel pan-PI3K inhibitors like BKM120, PX866
and XL147 are currently in clinical trials, selective inhibi-
tors for p110 isoforms that may display less off-target
effects and toxicities are attractive options for GBM treat-
ment [7]. Recently, The p110α-selective inhibitor BYL719
and the p110δ-selective inhibitor CAL-101 have already en-
tered phase I/II clinical trials and exhibited moderate anti-
proliferative and pro-apoptotic activities in solid tumors or
hematologic malignancies [8, 9]. Therefore, PI3K p110
isoforms are promising targets for GBM treatment.
Considering that inhibition of PI3K isoforms might
be compensated by other signaling pathways which
subsequently compromises the inhibitory effects, it is
critical to investigate combination therapy through tar-
geting PI3K and other molecules. The c-Jun N-terminal
kinase (JNK) plays important roles in the apoptosis and
motility of cancer cells, and has crosstalk with Akt
signaling. A number of studies find that JNK activation
is frequently accompanied by activation of Akt and
PI3K in tumor cells upon PTEN loss or epidermal
growth factor receptor (EGFR) overexpression [10–12].
In addition, JNK can be activated by growth factors and
G protein–coupled receptors (GPCRs) and is constitu-
tively activated in glioblastoma, indicating that the JNK
pathway may have crosstalk with PI3K/Akt pathway, and
they may share the same upstream signaling components
[13, 14]. Therefore, combined inhibition of class IA PI3K
catalytic isoforms and JNK may have synergistic effect on
glioblastoma cells.
Here we demonstrated that isoform-selective PI3K
inhibitors and JNK inhibitor exhibited divergent ef-
fects on the proliferation, migration and invasion of
glioblastoma cells in vitro. Inhibition of p110β or
p110δ, but not p110α, exerted synergism with JNK on
impeding glioblastoma cell proliferation and migration
through decreasing Akt, focal adhesion kinase (FAK)
and zyxin phosphorylation, resulting in the blockade
of lamellipodia and membrane ruffles formation.
Further, combined inhibition of p110β and JNK effect-
ively reduced xenograft tumor growth in vivo. These
results suggested that combined inhibition of p110β
and JNK may be an effective therapy for glioblastoma
treatment.
Methods
All experimental protocols used in this study were ap-
proved by the Hong Kong Polytechnic University
Health and Safety Committee and the Ethics Review
Board of Sun Yat-sen University Cancer Center.
Cell culture
Normal human astrocytes cell line was purchased from
ScienCell Research Laboratories. Human glioblastoma
cell lines U87-MG and U-373 MG were obtained from
ATCC. Cells were cultured in Minimum Essential Medium
Alpha (α-MEM) (Gibco) supplemented with 10 % (v/v) fetal
bovine serum (FBS) (Gibco). Cells were incubated at 37 °C
in 5 % CO2 atm.
Reagents and antibodies
Monoclonal anti-Akt (#9272) anti-phospho-Akt (Ser473)
(#9271), anti-phospho-Akt (Thr308) (#9275), anti-SAPK/
JNK (#9258), anti-phospho-SAPK/JNK (Thr183/Tyr185)
(#9251), anti-c-Jun (#9165), anti-phospho-c-Jun (Ser63)
(#2361), anti-FAK (#3285), anti-phospho-FAK (Tyr925)
(#3284), anti-zyxin (#3553), anti-phospho-zyxin (Ser142/
143) (#8467), anti-GAPDH (#2118) and horseradish
peroxidise (HRP)-conjugated secondary antibodies were
purchased from Cell Signaling Technology. Polyclonal
anti-β-actin (sc-1616) were obtained from Santa Cruz
Biotechnology. CAL-101, PIK-75 and TGX-221 were ob-
tained from Selleck Chemicals. SP600125 was from
Sigma-Aldrich. Drug treatment was generally performed
in α-MEM medium supplemented with 10 % FBS, unless
the additional illustration.
Cell proliferation assay
Cells were seeded onto 96-well plates (2000 cells per
well). On the next day cells were treated with inhibitors
for 48 h. The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay was performed by
adding 20 μL of MTT to each well followed by incubation
for 4 h at 37 °C. The formazan crystal was subsequently
dissolved in 150 μL of dimethyl sulfoxide (DMSO). Ab-
sorbance at 570 nm was determined by Benchmark Plus™
microplate spectrophotometer (BIO-RAD). Combination
effect was evaluated by combination index (CI) as de-
scribed by Chou [15]. Fraction affected (FA) refers to the
inhibition of cell proliferation and is calculated by: FA = 1-
(% cell proliferation/100). According to the FA values, CI
was calculated by Compusyn software. CI <0.9 indicates
synergistic effect; CI >1.1 indicates antagonistic effect; CI
between 0.9 and 1.1 indicates additive effect. Experiments
were carried out for at least three times and each inde-
pendent experiment consisted of four replicates.
Wound healing assay
Glioblastoma cells were seeded onto 12-well plates
(3 × 105 cells per well) and then incubated for 24 h to
achieve 90-100 % confluence. Cells were pretreated
with 5 μg/mL mitomycin C for 1 h to eliminate the
interference by cell proliferation. Wounds on the con-
fluent cells were created using a sterile 200 μL pipette
tip. After rinsed with phosphate-buffered saline (PBS)
Zhao et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:78 Page 2 of 14
for 3 times cells were treated with inhibitor in α-MEM
medium supplemented with 5 % FBS and then incubated
for 24 h at 37 °C. Cells were photographed immediately
after inhibitor treatment (time zero) and at 24 h after
wounding. Cell migration rate was indicated as the num-
ber of cells migrating into the original wounds.
Immunofluoresescence
Glioblastoma cells were seeded onto sterile coverslips in
24-well plates (2.5 × 104 cells per well) and incubated for
24 h at 37 °C. After 3-h inhibitor treatment cells were
fixed with 4 % paraformaldehyde for 15 min and then
permeabilized with 0.25 % Triton X-100 for 10 min at
room temperature. Coverslips were blocked with 1 % bo-
vine serum albumin (BSA) for 30 min, then incubated
with Alexa Fluor 594-conjugated phalloidin (Invitrogen)
for 20 min to visualize actin filaments. Cells were air
dried and mounted with ProLong Gold antifade mount-
ant with DAPI stain (Invitrogen). Lamellipodia were ana-
lyzed under Leica TSC SP8 confocal laser scanning
microscope and membrane ruffles were observed by
phase contrast microscopy. In each case, about 200 cells
were photographed and representative cells were shown.
Independent experiments were carried out in triplicate.
Invasion assay
Invasiveness of glioblastoma cells was determined using
BioCoat™ Matrigel™ Invasion Chamber (BD Bioscience).
Briefly the transwell inserts with 8 μm pores and pre-
coated Matrigel was rehydrated for 2 h at 37 °C. U-87
MG cells were pretreated with inhibitor in serum-free
medium for 1 h at 37 °C prior to seeding onto the insert
(2.5 × 104 cells per insert). Medium supplemented with
5 % FBS in each well of companion plate was served as a
chemoattractant. After 24-h incubation, the matrigel
layer and non-invasive cells in upper surface of the
membrane was removed. Cells in the lower surfaces of
the membrane were fixed with absolute methanol and
were then stained with 0.1 % crystal violet solution. Cells
were photographed under a light microscope at 100×
magnification and invasive cells from at least 10 repre-
sentative fields were counted using ImageJ software. In-
dependent experiments were carried out in triplicate.
Western blotting
Total proteins were extracted by RIPA lysis buffer and
protein concentrations were determined using the BCA
protein assay (Thermo Scientific). Proteins were then
separated by 8 % SDS-PAGE and transferred to PVDF
membranes (Millipore). After blocking with 5 % non-fat
milk or 5 % BSA for 2 h membranes were incubated
with gentle agitation in primary antibodies (1:1000) over-
night at 4 °C and then in HRP-conjugated secondary
antibodies (1:5000) for 1 h at room temperature. Positive
signals were visualized by ECL chemiluminescence using
ChemiDoc MP Imaging System (Bio-Rad).
Tumor xenograft for combination treatment in vivo
For in vivo tumor growth study 100 μL of U-87 MG
cells (5 × 106 cells) were subcutaneously injected into the
lower flanks of 5-week-old Balb/C nude mice (female,
16–20 g, Vital River Laboratories). Once the tumors
reached an average volume of ~70-80 mm3, mice (n = 6
of each group) were intraperitoneally injected once daily
for 7 days with vehicle, TGX-221 (40 mg/kg) and CAL-
101 (20 mg/kg) alone, or in combination with SP600125
(40 mg/kg). Ten percent DMSO (v/v), 30 % polyethylene
glycol 400 (v/v), 1 % Tween 80 (v/v) and 59 % saline
(v/v) was used as vehicle control. Tumor volumes were
determined by caliper measurement every 2–3 days, and
calculated by the formula: Volume = (width)2 x length/2,
where length is the longest diameter and width is the
shortest diameter perpendicular to length.
Statistical analysis
Data were presented as mean ± S.E.M and analyzed by
SPSS v22.0. Curves and histograms were drawn using
GraphPad PRISM v5.0. Statistical comparisons among
groups in proliferation invasion and migration assays
were evaluated by One-way ANOVA and Post Hoc
multiple comparison Tukey HSD test. For in vivo study,
comparisons of tumor volumes among groups were
assessed by One-way repeated measures ANOVA and
Post Hoc multiple comparison Tukey HSD test. The
difference was considered to be significant at p <0.05.
Results
Isoform-selective PI3K inhibitors suppress glioblastoma
cell proliferation and Akt signaling
Three PI3K inhibitors PIK-75 TGX-221 and CAL-110,
with selectivity towards p110 catalytic isoforms p110α,
p110β and p110δ respectively, were employed in this
study (Additional file 1: Table S1). We first investigated
the effects of these inhibitors on cell proliferation in
glioblastoma cell line U-87 MG. Cells were incubated
with PIK-75, TGX-221 and CAL-101 respectively at vari-
ous concentrations for 48 h. The p110α inhibitor PIK-75
displayed dose-dependent inhibitory effect on U-87 MG
cell proliferation and Akt signaling (Fig. 1a, e). Cell via-
bility of U-87MG cells was reduced significantly upon
PIK-75 treatment (≥0.0675 μM) (Fig. 1a). In contrast,
although the phosphorylation levels of Akt at both serine
473 (Ser473) and threonine 308 (Thr308) residues were
reduced after the treatment, the p110β inhibitor TGX-
221 did not show any significant inhibitory effect, indi-
cating that p110β possesses kinase-independent function
to maintain cell viability (Fig. 1b, f ). Compared with
PIK-75, the p110δ inhibitor CAL-101 also suppressed U-
Zhao et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:78 Page 3 of 14
87 MG cell proliferation and Akt phosphorylation in a
dose-dependent manner but was less effective (Fig. 1c, g).
The values of half maximal inhibitory concentration (IC50)
of PIK-75, TGX-221 and CAL-101 were 0.09 μM,
484.82 μM and 39.11 μM respectively (Additional file
1: Figure S1). The inhibitory effects of these three inhibi-
tors on another glioblastoma cell line U-373 MG were
similar to U-87 MG cells (Additional file 1: Figure S2).
Combined inhibition of p110β/δ and JNK exerts
synergistic effect on blockade of glioblastoma cell
proliferation in vitro
SP600125 is a JNK inhibitor with broad spectrum for
JNK1 JNK2 and JNK3 (Additional file 1: Table S2). We
analyzed the effect of SP600125 on U-87 MG cell prolifer-
ation and JNK signaling. Similar to PIK-75 and CAL-101,
SP600125 significantly suppressed cell proliferation in a
dose-dependent manner with an IC50 of 20.43 μM (Fig. 1d,
Additional file 1: Figure S1). SP600125 decreased phos-
phorylation level of c-Jun, a substrate of JNK, whereas
JNK phosphorylation was not affected (Fig. 1h).
To evaluate the combination effects of isoform-
selective PI3K inhibitors and SP600125 on glioblastoma
cell proliferation U-87 MG cells were simultaneously
treated with the inhibitors alone or in combination for
48 h. FA-CI plots were generated to evaluate the com-
bination effect (Fig. 2a-c). The combination of PIK-75
and SP600125 showed antagonistic effects on U-87 MG
cell proliferation with CI >1.1, whereas TGX-221/CAL-
101 and SP600125 exhibited a moderate synergistic
effect with CI <0.9 (Table 1, Additional file 1: Table S3).
Interestingly too low or too high concentration of
TGX-221 did not synergize with SP600125, indicating
that the combination effect of TGX-221 and SP600125
may be dose-dependent (Table 1).
According to the findings from Western blotting and
combination treatment we chose PIK-75 (0.1 μM), TGX-
221 (20 μM), CAL-101 (10 μM) and SP600125 (20 μM)
to conduct the subsequent experiments on glioblastoma
cell migration and invasion. U-87 MG cells treated with
inhibitors at these concentrations showed less cytotox-
icity but significant inhibition of Akt or JNK signaling.
Further, combination of TGX-221 and SP600125, as well
as CAL-101 and SP600125 displayed synergistic effects
at these concentrations. To investigate whether the
combination treatment was time-dependent, U-87 MG
cells were treated with PIK-75, TGX-221, or CAL-101
combined with SP600125 for 24, 48, 72 and 96 h. The
inhibitory effects of drug combinations (TGX-221 and
SP600125, CAL-101 and SP600125) were time-dependent,
and SP600125 potentiated the inhibitory effect of TGX-221
or CAL-101 at 24, 48, 72 and 96 h (Fig. 2e-f). PIK-75 or
SP600125 alone significantly inhibited cell viability in a
time-dependent manner. However, combined treatment of
PIK-75 and SP600125 attenuated the inhibitory effect of
PIK-75, being in accordance with the observation that
PIK-75 and SP600125 were antagonistic (Fig. 2d).
Taken together, TGX-221 or CAL-101 synergized with
SP600125 on glioblastoma cell proliferation inhibition
in dose- and time- dependent manners, whereas com-
bination of PIK-75 and SP600125 showed an antagon-
istic effect. Similar results were also found in U-373
Fig. 1 Inhibitory effects of PIK-75, TGX-221, CAL-101 and SP600125 on glioblastoma cell proliferation and signaling transduction. a-d U-87 MG cells
were treated with PIK-75, TGX-221, CAL-101 or SP600125 at different concentrations for 48 h. DMSO was used as a carrier control. Cell viability of U-87
MG cells sharply decreased when treated with PIK-75, CAL-101 and SP600125, whereas TGX-221 had no significant inhibitory effect (n = 3; p values
were determined by One-way ANOVA and Post Hoc multiple comparison Tukey HSD test. *: p <0.05; **: p <0.01; ***: p <0.001). e-g Isoform-selective
PI3K inhibitors PIK-75, TGX-221 and CAL-101 dramatically inhibited Akt phosphorylation at Ser473 and Thr308. h JNK inhibitor SP600125 suppressed
JNK signaling via reducing c-Jun phosphorylation, whereas JNK phosphorylation was not affected
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MG cells, suggesting that the combination effect may
not be cell line-specific (Additional file 1: Figure S3).
Western blotting was carried out to investigate the
effects of drug combination on Akt and JNK signaling. It
was found that JNK inhibitor not only inhibited c-Jun
phosphorylation but also attenuated Akt phosphorylation
at Thr308 (Fig. 2g-i). More importantly, combination of
TGX-221/CAL-101 and SP600125 had higher inhibition
of Akt phosphorylation at Thr308, but not at Ser473 and
c-Jun phosphorylation (Fig. 2h, i). No significant change of
Akt and c-Jun phosphorylation levels was observed in the
combination of PIK-75 and SP600125 (Fig. 2g). Interest-
ingly, inhibition of p110β remarkably suppressed c-Jun
phosphorylation, but no further suppression was observed
Fig. 2 Combination effects of isoform-selective PI3K inhibitors and SP600125 on glioblastoma cell proliferation. a-c FA-CI plots were generated
using Chou-Talalay method. U-87 MG cells were treated with two inhibitors at a fixed ratio for 48 h. d-e U-87 MG cells were treated with PIK-75
(0.1 μM), TGX-221 (20 μM) or CAL-101 (10 μM) alone and combined with SP600125 (20 μM) for 24, 48, 72 and 96 h respectively. DMSO was used
as a carrier control. Antagonistic effect was found in the combination of PIK-75 and SP600125, whereas SP600125 significantly synergized with
TGX-221 or CAL-101 (n = 3; p values were determined by Two-way ANOVA and Post Hoc multiple comparison Tukey HSD test. ***: p <0.001). g-i
U-87 MG cells were treated with PIK-75, TGX-221 or CAL-101 alone and combined with SP600125 for 3 h. Phosphorylation level of Akt was also
downregulated by SP600125. Combination of TGX-211 and SP600125, as well as CAL-101 and SP600125 exhibited higher inhibition of Akt
phosphorylation at Thr308










PIK-75 + SP600125 TGX-221 + SP600125 CAL-101 + SP600125
0.01 2 1 2 1.333 ± 0.169 1.252 ± 0.040 1.614 ± 0.169
0.025 5 2.5 5 1.645 ± 0.082 0.907 ± 0.005 1.263 ± 0.301
0.05 10 5 10 1.595 ± 0.061 0.837 ± 0.001 0.911 ± 0.107
0.1 20 10 20 1.568 ± 0.047 0.855 ± 0.055 0.809 ± 0.018
0.2 40 20 40 2.104 ± 0.103 1.009 ± 0.125 0.700 ± 0.049
aData were presented as mean ± S.E.M. CI <0.9 indicates synergistic effects; CI >1.1 indicates antagonistic effects; CI between 0.9 and 1.1 indicates additive effects
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when JNK was also inhibited (Fig. 2h). This suggested that
p110β and JNK may act on c-Jun via the same pathway.
Additionally experiments were also conducted in nor-
mal human astrocytes to evaluate the combination effects
on normal brain cells. Treatments of PIK-75, TGX-221,
CAL-101 and SP600125 alone, as well as their combin-
ation showed lower cytotoxicities to astrocytes than U-87
MG cells (Additional file 1: Figure S3).
Inhibition of JNK potentiates the inhibitory effect of
p110β/δ inhibitor on glioblastoma cell migration but not
invasion
To investigate the combination effects of isoform-selective
PI3K inhibitors and SP600125 on glioblastoma cell motility
wound was generated in U-87 MG cells which were then
treated with PIK-75 (0.1 μM), TGX-221 (20 μM), or CAL-
101 (10 μM) combined with SP600125 (20 μM) for 24 h. In
Fig. 3 SP600125 potentiated inhibitory effects of isoform-selective PI3K inhibitors on glioblastoma cell migration. a Number of viable U-87 MG
cells was counted using Vi-Cell Cell Viability Analyzer (Beckman Coulter) before and after treatment of mitomycin C for 24 h. Cell proliferation was
inhibited by mitomycin C at 5 or 10 μg/mL without impairing viability. b Wound healing in U-87 MG cells treated with PIK-75 (0.1 μM), TGX-221
(20 μM) or CAL-101 (10 μM) alone and combined with SP600125 (20 μM) for 24 h. Cells were pretreated with 5 μg/mL of mitomycin C for 1 h.
The lines indicate the edge of wound generated before drug treatment (0 h). Photographs were obtained at 50× magnification. c-e Migration rate
was analyzed and expressed as the number of cells migrating into the original wounds. U-87 MG cell migration was blocked by PIK-75, TGX-221, CAL-101
and SP600125 alone. Inhibition of migration rate was reinforced by the combined treatment of TGX-221 and SP600125, as well as CAL-101 and SP600125
(n= 3; p values were determined by One-way ANOVA and Post Hoc multiple comparison Tukey HSD test. *: p <0.05; **: p <0.01; ***: p <0.001)
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order to exclude the effect of cell proliferation, cells were
incubated with mitomycin C prior to wound production
and inhibitor treatment. It was found that mitomycin C at
5–10 μg/mL effectively inhibited glioblastoma cell growth
without decreasing the live cell number (Fig. 3a). Therefore,
5 μg/mL was considered as the optimal concentration of
mitomycin C to block glioblastoma cell proliferation. As
shown in Fig. 3, PIK-75, TGX-221, CAL-101 and
SP600125 were capable of preventing U-87 MG cells
migrating into the wound to different extent. The capacity
of blocking migration is roughly ranked as followed:
PIK-75 ≈ SP600125 > TGX-221 > CAL-101. Combination
of TGX-221 or CAL-101 combined with SP600125 poten-
tiated the inhibitory effects on glioblastoma cell migration,
whereas PIK-75 and SP600125 did not (Fig. 3e-g). Simi-
lar inhibitory effects were also observed in U-373 MG
cells, in spite of the fact that only PIK-75 was sufficient
to block the migration of these cells (Additional file 1:
Figure S4).
To analyze the effects of isoform-selectivePI3K inhibi-
tors in combination with SP600125 on glioblastoma cell
invasion Boyden chamber invasion assay was performed
on U-87 MG and U-373 MG cells. Number of invasive
cells was markedly decreased by PIK-75 and SP600125,
whereas neither TGX-221 nor CAL-101 inhibited glio-
blastoma cell invasion (Fig. 4). No synergistic effect was
found with combination treatment on cell invasion (Fig. 4
and Additional file 1: Figure S5).
Combined inhibition of p110β/δ and JNK restrains
lamellipodia and membrane ruffles formation through
decreased FAK or zyxin activation
Actin remodeling which includes formation of lamellipodia
and membrane ruffles is essential to cell migration. There-
fore we assessed the effects of isoform-selective PI3K inhib-
itors and JNK inhibitor on lamellipodia and membrane
ruffles formation in glioblastoma cells by labeling actin fila-
ments after 3-h drug treatment. Number of U-87 MG cells
with lamellipodia and membrane ruffles was significantly
decreased after treatment with inhibitors alone (Fig. 5).
Interestingly, among the isoform-selective PI3K inhibitors,
inhibition of membrane ruffles formation was the highest
upon the treatment of the p110β inhibitor, whereas lamelli-
podia formation was most significantly impaired when
treated with the p110α inhibitor, suggesting that p110β may
be required for membrane ruffles formation, while p110α is
essential for lamellipodia formation. Combination of TGX-
221/CAL-101 and SP600125 potentiated the inhibitory ef-
fects, whereas PIK-75 and SP600125 did not.
To elucidate the molecular mechanism contributing to
the synergistic effect of isoform-selective PI3K inhibitors
and JNK inhibitor on cell migration activation of focal
Fig. 4 No synergistic effect on glioblastoma cell invasion was observed in the combination of isoform-selective PI3K inhibitors and SP600125. Boyden
chamber invasion assay of U-87 MG cells treated with PIK-75 (0.1 μM), TGX-221 (20 μM) or CAL-101 (10 μM) alone and combined with SP600125
(20 μM) for 24 h. a Representative photographs showing the invasive cells that had passed through matrigel to the lower surface of the membrane at
100× magnification. Invaded cells from 5 representative fields were counted. b-d Number of invasive cells was significantly decreased by PIK-75 and
SP600125, and all the combinations did not enhanced the inhibitory effect (n = 3; p values were determined by One-way ANOVA and Post
Hoc multiple comparison Tukey HSD test. *: p <0.05; **: p <0.01)
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Fig. 5 (See legend on next page.)
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adhesion and cytoskeleton-related signaling network were
investigated. After 24-h drug treatment, phosphorylation
level of FAK at Tyr925 in U-87 MG cells was decreased
upon inhibition of p110 isoforms and JNK, whereas the
phosphorylation level of zyxin was only reduced by inhib-
ition of JNK (Fig. 6a-c). Moreover, combination of TGX-
221 and SP600125 showed lower FAK phosphorylation
level, while combination of CAL-101 and SP600125 dis-
played lower phosphorylation levels of both zyxin and
FAK (Fig. 6b-e). Thus, isoform-selective PI3K inhibitors
impeded glioblastoma cell migration through blockade of
FAK activation, and reduced FAK or zyxin activation con-
tributed to the synergistic inhibitory effects on glioblast-
oma cell migration.
Combined inhibition of p110β and JNK suppresses
xenograft tumor growth in vivo
The in vitro synergistic effects of p110β/δ inhibitors and
SP600125 on glioblastoma cell proliferation and migration
suggest that they may have similar anti-tumor activity in
vivo. To evaluate the combination effect of p110β/δ
and JNK inhibition on tumor growth Balb/C nude mice
bearing U-87 MG glioblastoma xenograft were treated
with vehicle, TGX-221 (40 mg/kg) and CAL-101 (20 mg/kg)
alone, or in combination with SP600125 (40 mg/kg). Only
SP600125 significantly suppressed U-87 MG xenograft
tumor growth after 24-day post-administration, whereas
TGX-221 or CAL-101 slightly decreased tumor volumes
(Fig. 7). Synergistic inhibitory effect on tumor growth was
Fig. 6 Isoform-selective PI3K inhibitors and SP600125 affected focal adhesion and cytoskeleton-related signaling. a-c U-87 MG cells were treated
with PIK-75 (0.1 μM), TGX-221 (20 μM) or CAL-101 (10 μM) alone and combined with SP600125 (20 μM) for 24 h. Whole cell lysates were separated by
SDA-PAGE, and the phosphorylated and total protein levels were determined by Western blotting using antibodies against the corresponding
phosphorylated and total proteins. Expression of GAPDH was served as a loading control. Data were representative of three independent
experiments. Density of FAK d and zyxin e phosphorylation levels were relative to total FAK and zyxin protein expression levels. Combination
of TGX-221 and SP600125 showed a higher inhibition of FAK phosphorylation, while combination of CAL-101 and SP600125 displayed higher
inhibition of FAK and zyxin phosphorylation (n = 3; p values were determined by One-way ANOVA and Post Hoc multiple comparison Tukey
HSD test. *: p <0.05; **: p <0.01)
(See figure on previous page.)
Fig. 5 SP600125 potentiated inhibitory effects of isoform-selective PI3K inhibitors on lamellipodia and membrane ruffles formation. a Immunocytochemistry
of U-87 MG cells stained with Alexa Fluor 594-conjugated phalloidin (red) after treatment with PIK-75 (0.1 μM), TGX-221 (20 μM) or CAL-101 (10 μM) alone
and combined with SP600125 (20 μM) for 3 h. Lamellipodia (white arrow) were decreased after inhibition of p110α, p110β, p110δ and JNK, while stress fibers
(arrowhead) were widely developed at the presence of SP600125. Bar = 50 μm. b-d Cells with lamellipodia were counted and data were
expressed as the ratio of number of cells with lamellipodia over total cell number. SP600125 potentiated the inhibitory effect of TGX-221
and CAL-101 on lamellipodia formation (n = 3; p values were determined by One-way ANOVA and Post Hoc multiple comparison Tukey
HSD test. ***: p <0.001). e Phase contrast microscopy of U-87 MG cells after treatment with PIK-75, TGX-221 or CAL-101 alone and combined with
SP600125 for 3 h. Cells with membrane ruffles (black arrow) were reduced by the treatment of isoform-selective PI3K inhibitors and SP600125.
Photographs were obtained at 200× magnification. f-h Cells with membrane ruffles were counted and data were expressed as the ratio of
number of cells with membrane ruffles over total cell number. SP600125 also enhanced the inhibitory effect of TGX-221 and CAL-101 on membrane
ruffles formation (n = 3; p values were determined by One-way ANOVA and Post Hoc multiple comparison Tukey HSD test. **: p <0.01; ***: p <0.001)
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observed in the combination treatment of TGX-221 and
SP600125, being consistent with the in vitro study
(Fig. 7a-b). Although combination of CAL-101 and
SP600125 effectively reduced tumor volume, there is no
significant difference between combination treatment
and single inhibitor alone (Fig. 7c-d). However, about
half of mice with combination treatment died on the
next day of intraperitoneal injection, while the remaining
mice with the same treatment did not show any adverse
reaction until sacrifice, suggesting that the death of mice
may be correlated with over-injection, and the therapeutic
tolerance of combination treatments was acceptable.
Discussion
The roles of class IA PI3K isoforms in the pathological
processes of glioblastoma, and the crosstalk between
PI3K and JNK are complicated. In this study, we employed
three selective inhibitors PIK-75, TGX-221 and CAL-101,
which targets p110α, p110β, and p110δ isoform respect-
ively, to investigate the effects of these catalytic subunits
on glioblastoma cells. We demonstrated that these PI3K
isoforms played distinct roles on proliferation, migration
and invasion of glioblastoma cells, even though their re-
spective inhibitors inhibited Akt phosphorylation at both
Ser473 and Thr308. Inhibition of p110α was sufficient to
suppress glioblastoma cell viability, migration and inva-
sion, whereas inhibition of p110β only blocked cell mi-
gration, and inhibition of p110δ moderately impeded
cell proliferation and migration. Our data indicated that
p110α is of more importance to glioblastoma cell viabil-
ity and motility than p110β and p110δ.
Accumulating evidence shows that the p110 isoforms
exert distinct roles in Akt phosphorylation and other
pathological processes [16, 17]. The p110α and p110β
display different preferences to RTK activation, but
p110β is also activated by GPCRs [18, 19]. Selective gene
knockdown and isoform-selective inhibitors are helpful
to investigate the individual role of class IA PI3K cata-
lytic isoforms. The p110α isoform is required for tumor
cell proliferation, migration and invasion, whereas p110β
is essential to cell survival and tumorigenesis [20–23].
Knockdown of PIK3CA (encoding p110α) significantly
inhibits cell viability and motility in medulloblastoma
and glioblastoma cells [20, 21]. The p110α isoform is
also vital to invasion of breast cancer cells through me-
diating invadopodia formation [24]. In addition, tumor
cell growth is effectively suppressed in vitro and in vivo
by using the p110α isoform-selective inhibitors A66,
BYL719 or PIK-75, while apoptosis and cell cycle arrest
are promoted [25–28]. Our findings are in agreement
with these studies. Knockdown of PIK3CB (encoding
p110β) suppresses cell proliferation and induces apop-
tosis in ovarian cancer and glioblastoma in vitro and in
vivo, suggesting p110β plays important roles in cell
growth [22, 29]. However, selective p110β inhibitor
TGX-221 does not affect cell proliferation or apoptosis,
but impedes migration in glioblastoma cells [30]. These
distinct outcomes between selective inhibitor and gene
knockout may be caused by kinase-independent function
of p110β [31]. In addition, targeting p110δ suppresses
cell growth, migration and invasion in neuroblastoma
and glioblastoma cells [32, 33]. Our previous study
shows that the p110δ-selective inhibitor IC87114 only
Fig. 7 Combined inhibition of p110β and JNK exerted synergism to suppress xenograft tumor growth in vivo. Human glioblastoma U-87 MG cells
(5 × 106 cells) were subcutaneously injected into the Balb/C nude mice. Nine days after inoculation, mice were intraperitoneally (i.p.) injected once
daily for 7 days with vehicle, TGX-221 (40 mg/kg) and CAL-101 (20 mg/kg) alone, or in combination with SP600125 (40 mg/kg). Measurement of
tumor volumes started on the day of the first administration. a, c Representative subcutaneous tumor xenografts from mice sacrificed after 37-day
post-administration. b, d Summary data of tumor volumes from 10-day post-administration to the end of the experiment. (n = 6; p values were
determined by One-way repeated measures ANOVA and Post Hoc multiple comparison Tukey HSD test. *: p <0.05; ***: p <0.001 compared
with vehicle control; a: p <0.05 compared with PI3K inhibitor; b: p <0.05 compared with SP600125)
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suppresses cell migration without affecting the invasive
capacity [33]. In this study, similar results were also
found in glioblastoma cells using inhibitor CAL-101
which had higher selectivity to p110δ. Similar to our
findings, Holand et al. found that PIK-75 significantly
inhibited T98G glioblastoma cell proliferation and col-
ony formation, while TGX-221 and IC87114 did not
show the inhibitory effects [30]. Taken together, con-
sistent results were obtained in glioblastoma cell lines
U-87 MG, U-373 MG and T98G with different genetic
background, suggesting that p110α is most essential
among three class IA PI3K catalytic isoforms, which
may be due to its predominant role in RTK-mediated
PI3K signaling. In contrast, inhibition of p110β and
p110δ exerts minor influence on cellular functions of
glioblastoma cells, which may be limited by the consti-
tutive activation of p110α [34].
The ATP-competitive JNK inhibitor SP600125 was
sufficient to inhibit cell viability, migration and invasion
of glioblastoma cells through decreasing the phosphoryl-
ation levels of both c-Jun and Akt. Activated JNK can
translocate into the nucleus and phosphorylate a variety
of transcription factors such as c-Jun, which is a compo-
nent of transcription factor activator protein-1 (AP-1).
AP-1 is able to regulate the transcriptional activity of
phosphoinositide-dependent kinase 1 (PDK1) and the
activation of its downstream target Akt, suggesting that
JNK regulates Akt activity through JNK/c-Jun/PDK1/Akt
axis [35]. Interestingly, we also found that only TGX-221
was able to decrease c-Jun phosphorylation level, which
was in accordance with the constitutive activation of
p110β contributing to the activation of JNK [10]. Our
data therefore suggest that p110β, not p110α nor p110δ,
may be an upstream regulator of JNK signaling, possibly
because they are both activated by GPCRs.
Combination therapy targeting PI3K/Akt pathway and
Ras-mediated MAPK pathway may exert synergism for
cancer treatment [36, 37]. Evidence shows that com-
bined inhibition of p110δ and mitogen-extracellular acti-
vated protein kinase (MEK) has synergistic cytotoxicity
in human acute myeloid leukemia progenitors [38].
Combination of MEK1/2 and PI3K/mTOR inhibitors
potentiates the inhibitory effects on cell proliferation
and angiogenesis in non-small cell lung carcinoma (NSCLC)
[39]. Concurrent expression of dominant-negative mitogen-
activated protein kinase kinase 4 (MKK4) and PI3K p85α
isoform is also synergistic to induce apoptosis in lung cancer
[40]. This kind of synergism is also noted in this study in
which combined inhibition of p110β/δ and JNK displayed
synergistic inhibitory effects on glioblastoma cell prolif-
eration and migration via blockade of Akt, zyxin and
FAK activation. Formation of lamellipodia and membrane
ruffles involved in cell migration was also suppressed. How-
ever, only PIK-75 and SP600125 suppressed glioblastoma
cell invasion, and all the combinations had no synergistic
effects, suggesting that the crosstalk between PI3K and JNK
in cell invasion is limited. Although the p110α isoform
plays a dominant role in the activation of PI3K/Akt signal-
ing, p110β modulates PI3K activity in a competitive man-
ner by competing against p110α for RTK binding [41].
Evidence shows that genetic deletion of PI3KCA suppresses
tumor formation of breast cancer, whereas loss of PIK3CB
leads to mammary gland hyperplasia and tumorigenesis, ac-
companied by increased PI3K activity and Akt phosphoryl-
ation level [41]. In addition, overexpression of p110β blocks
the EGF-induced migration in breast cancer cells, suggest-
ing abundant p110β may replace p110α to interact with
EGFR and results in deficiency of active p110α [42]. Since
p110α plays a dominant role in RTK-mediated Akt signal-
ing, inhibition of p110α by PIK-75 may lead to activation of
p110β due to a compensatory effect induced by GPCR acti-
vation, and then p110βmay activate JNK pathway to escape
from p110α inhibition. We also found that phosphorylation
level of c-Jun was elevated by treatment of PIK-75, indicat-
ing that inhibition of p110α may promote JNK activity
through activation of p110β/GPCR/JNK signaling axis. It
may explain why combined inhibition of p110α and JNK
was antagonism in our study. However, since PIK-75 dis-
plays an unexpected inhibition on DNA-PK, and BYL-719
exhibits better pharmaceutical properties, selectivity and
sensitivity to p110α than PIK-75, BYL-719 will be
employed in the future in vitro and in vivo study to
confirm our findings.
Being consistent with the in vitro study, synergistic in-
hibitory effect of combination between TGX-221 and
SP600125 on glioblastoma cell U-87 MG xenograft tumor
growth was also observed. However, siRNA-mediated gene
knockdown and pharmacological inhibition of the same
molecule may not generate the same effect. To confirm our
findings and figure out which JNK isoform participates in
the crosstalk with PI3K p110β, siRNAs targeting JNK1,
JNK2 and JNK3 respectively will be combined with p110β
inhibitor in the future study. Compared with vehicle con-
trol, treatment of CAL-101 did not decrease xenograft
tumor growth, indicating that p110δ plays a minor role in
glioblastoma growth. Although the combination of
CAL-101 and SP600125 remarkably reduced tumor
growth, there was no significant difference between
this combination and single inhibitor alone, suggesting
that higher dose of CAL-101 may be employed to aug-
ment the combination effect.
Cell migration is a complicated biological process in-
cluding actin polymerization, protrusion formation, ad-
hesion complexes formation, turnover of focal adhesion,
and retraction at the cell rear. A variety of cytoskeletal
structures including lamellipodia, filapodia, focal adhesion,
stress fibers, and membrane ruffles are essential to a mo-
tile cell, providing adhesion sites and contractile forces for
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cell movement. Focal adhesion complexes consisting of in-
tegrin, paxillin, talin, zyxin and FAK are formed at the
edge of lamellipodia to provide attachment of cell protru-
sion to the extracellular matrix [43]. Zyxin and FAK are
known as focal adhesion proteins mediating cell-matrix
adhesion and actin polymerization. Zyxin recruits En-
abled/vasodilator-stimulated phospho-protein (Ena/VASP)
through N-terminal ActA proline-rich domain to regulate
actin filament assembly, and facilitates focal adhesion by
interacting with specific proteins through C-terminal LIM
domains [44]. The interaction of LIM domains and adap-
tors required phosphorylation of zyxin at Ser142 [45]. Evi-
dence shows that knockdown or inhibition of zyxin leads
to blockade of cell spreading and migration [46]. Here, we
demonstrated that SP600125 markedly decreased zyxin
phosphorylation level, whereas none of the isoform-
selective PI3K inhibitors did so, suggesting that the
impact of JNK and PI3K inhibitors on downstream sig-
naling is different. Moreover, combination of CAL-101
and SP600125 synergistically reduced zyxin phosphoryl-
ation level than on their own. In addition, activation of
FAK is involved in cell adhesion, migration and inva-
sion. Autophosphorylation of FAK at Tyr397 leads to
recruitment of PI3K p85 subunit and phosphorylation
of FAK at Tyr925, and subsequently triggers the Ras-
dependent activation of MAPK pathway. FAK phosphoryl-
ation status at Tyr925 is crucial to cell migration and focal
adhesion turnover. Evidence reveals that expression of
nonphosphorylatable FAK at Tyr925 in FAK−/− mouse
embryonic fibroblasts (MEFs) reduces phosphorylation of
paxillin and activates Rac1, leading to stabilization of focal
adhesion, inhibition of cell protrusion and migration [47].
In this study, isoform-selective PI3K inhibitors and
SP600125 alone suppressed glioblastoma cell migra-
tion through inhibition of FAK phosphorylation at
Tyr925. Combination of TGX-221 and SP600125, as
well as CAL-101 and SP600125 also potentiated the
inhibitory effects on FAK phosphorylation.
Conclusions
In summary, the isoform-selective PI3K inhibitors dis-
played distinct effects on glioblastoma cell proliferation,
migration and invasion in vitro. Combined inhibition of
p110β and JNK exhibited synergistic effects on suppress-
ing glioblastoma cell proliferation and migration in vitro
and xenograft tumor growth in vivo through decreasing
Akt and FAK phosphorylation, resulting in the blockade
of lamellipodia and membrane ruffles formation. More
importantly, these inhibitors, either alone or in combin-
ation, were much less toxic to astrocytes than glioblast-
oma cells in vitro. Preclinical study also suggested that
the toxicity was tolerable in mice. Taken together, com-
bination therapy via concurrent inhibition of PI3K and
JNK may be a promising approach for glioblastoma mul-
tiforme treatment.
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